Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions von McGinley, Marisa P, Cohen, Jeffrey A

Volltext

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis von Cohen, Jeffrey A., Chun, Jerold

Volltext

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function von Ontaneda, Daniel, MD, Thompson, Alan J, Prof, Fox, Robert J, Prof, Cohen, Jeffrey A, Dr Prof

Volltext

Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis von Chaudhry, Burhan Z., Cohen, Jeffrey A., Conway, Devon S.

Volltext

Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis von Subei, Adnan M., Cohen, Jeffrey A.

Volltext

Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis von Strober, Lauren, DeLuca, John, Benedict, Ralph HB, Jacobs, Adam, Cohen, Jeffrey A, Chiaravalloti, Nancy, Hudson, Lynn D, Rudick, Richard A, LaRocca, Nicholas G

Volltext

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria von Polman, Chris H., Reingold, Stephen C., Banwell, Brenda, Clanet, Michel, Cohen, Jeffrey A., Filippi, Massimo, Fujihara, Kazuo, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Lublin, Fred D., Montalban, Xavier, O'Connor, Paul, Sandberg-Wollheim, Magnhild, Thompson, Alan J., Waubant, Emmanuelle, Weinshenker, Brian, Wolinsky, Jerry S.

Volltext

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial von Cohen, Jeffrey A, Dr, Arnold, Douglas L, MD, Comi, Giancarlo, MD, Bar-Or, Amit, MD, Gujrathi, Sheila, MD, Hartung, Jeffrey P, PhD, Cravets, Matt, MA, Olson, Allan, MD, Frohna, Paul A, MD, Selmaj, Krzysztof W, MD

Volltext

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects von Cohen, Jeffrey A, Prof, Reingold, Stephen C, PhD, Polman, Chris H, Prof, Wolinsky, Jerry S, Prof

Volltext

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial von Coles, Alasdair J, Dr, Twyman, Cary L, MD, Arnold, Douglas L, Prof, Cohen, Jeffrey A, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Miller, Tamara, MD, Fisher, Elizabeth, PhD, Sandbrink, Rupert, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Oyuela, Pedro, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

Volltext

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial von Cohen, Jeffrey A, Prof, Coles, Alasdair J, PhD, Arnold, Douglas L, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Fisher, Elizabeth, PhD, Brinar, Vesna V, MD, Giovannoni, Gavin, Prof, Stojanovic, Miroslav, MD, Ertik, Bella I, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

Volltext

Applying the 2017 McDonald diagnostic criteria for multiple sclerosis – Authors' reply von Thompson, Alan J, Reingold, Stephen C, Cohen, Jeffrey A

Volltext

Combination therapy in multiple sclerosis von Conway, Devon, MD, Cohen, Jeffrey A, MD

Volltext

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results von Cohen, Jeffrey A., Tenenbaum, Nadia, Bhatt, Alit, Zhang, Ying, Kappos, Ludwig

Volltext

Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics von Ontaneda, Daniel, Hyland, Megan, Cohen, Jeffrey A

Volltext

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study von Khatri, Bhupendra, Dr, Barkhof, Frederik, MD, Comi, Giancarlo, MD, Hartung, Hans-Peter, MD, Kappos, Ludwig, MD, Montalban, Xavier, MD, Pelletier, Jean, MD, Stites, Tracy, PhD, Wu, Stacy, MD, Holdbrook, Fred, PhD, Zhang-Auberson, Lixin, MD, Francis, Gordon, MD, Cohen, Jeffrey A, MD

Volltext

Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate? von Mirabella, Massimiliano, Annovazzi, Pietro, Brownlee, Wallace, Cohen, Jeffrey A, Kleinschnitz, Christoph, Wolf, Christian

Volltext

Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid‐Dependent Mechanism von Rozenberg, Ayal, Rezk, Ayman, Boivin, Marie-Noëlle, Darlington, Peter J., Nyirenda, Mukanthu, Li, Rui, Jalili, Farzaneh, Winer, Raz, Artsy, Elinor A., Uccelli, Antonio, Reese, Jane S., Planchon, Sarah M., Cohen, Jeffrey A., Bar-Or, Amit

Volltext

Commentary: Solomon AJ et al. Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. Lancet Neurol 2023; 22(8): 750–768 von Cohen, Jeffrey A

Volltext

Women's Health in Multiple Sclerosis: A Scoping Review von Ross, Lindsay, Ng, Huah Shin, O'Mahony, Julia, Amato, Maria Pia, Cohen, Jeffrey A, Harnegie, Mary Pat, Hellwig, Kerstin, Tintore, Mar, Vukusic, Sandra, Marrie, Ruth Ann

Volltext